

## Pneumococcal Immunization Recommendations for those 65 Years and Older

Risk of IPD	Pneumococcal Vaccine History		Eligibility for Pneu-C-20
	Pneu-P-23	Pneu-C-13	
<b>Low Risk</b>	0 doses	Not eligible	1 dose
	1 dose at ≥65 years	Not eligible	None
<b>High Risk</b> *criteria 1-7	0 to 3 doses	0 doses	1 dose
	0 to 2 doses	1 dose	Given at least 1 year after last dose of Pneu-P-23 and 8 weeks after last dose of Pneu-C-13 (if applicable)
	3 doses, with at least 1 dose at age ≥65 years	1 dose	None
<b>High Risk</b> *criteria 8-9	0 to 2 doses	Not eligible	1 dose
	3 doses, with at least 1 dose ≥65 years	Not eligible	None
<b>High Risk</b> *criteria 10-17	0 to 1 dose	Not eligible	1 dose Given at least 1 year after last dose of Pneu-P-23 (if applicable)
	2 doses, with at least 1 dose ≥65 years	Not eligible	None

### High Risk Eligibility Criteria

1. Asplenia (functional or anatomic), splenic dysfunction
2. Congenital (primary) immunodeficiencies involving any part of the immune system, include B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions.
3. HIV infection
4. Immunocompromising therapy including use of long-term systemic corticosteroid, chemotherapy, radiation therapy, post-organ transplant therapy, certain anti-rheumatic drugs and other immunosuppressive therapy.
5. Malignant neoplasms, including leukemia and lymphoma.
6. Sickle-cell disease and other sickle cell hemoglobinopathies.
7. Solid organ or islet cell transplant (recipient)
8. Hepatic cirrhosis due to any cause.
9. Chronic renal disease, including nephrotic syndrome.
10. Chronic cardiac disease.
11. Chronic liver disease, including hepatitis B and C.
12. Chronic respiratory disease, excluding asthma, except those treated with high-dose corticosteroid therapy.
13. Chronic neurologic conditions that may impair clearance of oral secretions.
14. Diabetes mellitus.
15. Cochlear implant recipients (pre/post implant).
16. Chronic cerebral spinal fluid leak.
17. Residents of nursing homes, homes for the aged and chronic care facilities or wards.
18. Hematopoietic stem cell transplant (HSCT) recipients → **Refer to page two.**

Pneu-P-23: pneumococcal polysaccharide 23-valent vaccine (Pneumovax® 23)

Pneu-C-13: pneumococcal conjugate 13-valent vaccine (Prevnar 13®)

Pneu-C-20: pneumococcal 20-valent conjugate vaccine (Prevnar 20®)

## Pneumococcal Immunization Recommendations for those 65 Years and Older Post Hematopoietic Stem Cell Transplant (HSCT)

Risk of IPD	Pneumococcal Vaccine History		Eligibility for Pneu-C-20
	Pneu-P-23	Pneu-C-13	
<b>Post HSCT</b>	0 to 3 doses	0 doses or Incomplete series	See table below.  To be given 1 year after last dose of Pneu-P-23 (if applicable)
	0 to 2 doses	Completed series	1 dose Given at least 1 year after last dose of Pneu-P-23 and 8 weeks after last dose of Pneu-C-13 (if applicable)
	3 doses, with at least 1 dose at age ≥65 years	Completed series	None

Schedule for Pneu-C-20 for HSCT Recipients ≥65 Years Who Have Not Completed or Have Not Started Pneu-C-13 Vaccines Series Post-Transplant	
History of Publicly Funded Pneu-C-13 Post HSCT	Recommended # of Pneu-C-20 doses required to complete series and recommended interval
0 doses post HSCT	1 <sup>st</sup> dose, 3-9 months post HSCT 2 <sup>nd</sup> dose, 4 weeks after 1 <sup>st</sup> dose 3 <sup>rd</sup> dose, 4 weeks after 2 <sup>nd</sup> dose 4 <sup>th</sup> dose, 12-18 months post-transplant and 6-12 months after 3 <sup>rd</sup> dose
1 dose post HSCT (1 <sup>st</sup> dose)	2 <sup>nd</sup> dose, 4 weeks after 1 <sup>st</sup> dose 3 <sup>rd</sup> dose, 4 weeks after 2 <sup>nd</sup> dose 4 <sup>th</sup> dose, 12-18 months post-transplant and 6-12 months after 3 <sup>rd</sup> dose
2 doses post HSCT (1 <sup>st</sup> and 2 <sup>nd</sup> doses)	3 <sup>rd</sup> dose, 4 weeks after 2 <sup>nd</sup> dose 4 <sup>th</sup> dose, 12-18 months post-transplant and 6-12 months after 3 <sup>rd</sup> dose
3 doses post HSCT (1 <sup>st</sup> , 2 <sup>nd</sup> and 3 <sup>rd</sup> dose)	4 <sup>th</sup> dose, 12-18 months post-transplant and 6-12 months after 3 <sup>rd</sup> dose

**For recommendations for those who are under 65 years of age, refer to the following documents:**

[HCP Fact Sheet: Pneumococcal Conjugate Vaccines for Children Aged 6 Weeks to 17 Years](#)  
[HCP Fact Sheet: Pneumococcal Conjugate Vaccine for Individuals Aged 18 Years and Older](#)

### Long-term care facilities

Regardless of their pneumococcal vaccination history with Pneu-C-13 or Pneu-P-23, individuals who live in communities or settings experiencing sustained high IPD rates, including those residing in long term care facilities (or children in residential care for complex medical needs), should receive pneumococcal vaccination. Adults and children should receive Pneu-C-20.